Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 40.5M | 11.66% |
| Gross profit | 26.7M | 8.64% |
| Net profit | 6.47M | 4.12% |
| EBITDA | 11.1M | 3.70% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €712.39M |
Number of shares | 9.58M |
52-week high/low | €95.90 - €44.60 |
Dividend yield | 1.61% |
Dividends TTM | €1.20 |
Beta | 0.18 |
P/E ratio | 34.13 |
PEG ratio | 1.47 |
P/B ratio | 10.23 |
P/S ratio | 4.99 |
Company profile
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.
| Name | PHARMANUTRA S.P.A. |
| CEO | Andrea Lacorte |
| Headquarters | Pisa,
pi Italy |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 07/18/2017 |
| Employees | 144 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Mil | PHN.MI |
Frankfurt | 761.F |
Düsseldorf | 761.DU |
Milan | PHN.MI |
München | 761.MU |